Novel agents in gastroenteropancreatic neuroendocrine tumors: Highlights from the "2013 ASCO gastrointestinal cancers symposium". San Francisco, CA, USA. january 24-26, 2013

Ryan Stevenson, Steven K. Libutti, Muhammad Wasif Saif

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Neuroendocrine tumors (NET) are a diverse group of tumors that derive from epithelial cells with neuroendocrine differentiation. Gastroenteropancreatic neuroendocrine tumors are a subset of NET that arises in the gastrointestinal tract. Clinical symptoms and presentations vary depending on the location and hormones produced by the tumor. Treatment of advanced and metastatic gastroenteropancreatic NETs has traditionally been difficult with few systemic treatment options. In 2011, two new targeted therapies, everolimus and sunitinib were approved for treatment of pancreatic NET leading to increased interest in novel agents active in gastroenteropancreatic NETs. At the 2013 ASCO Gastrointestinal Cancers Symposium two abstracts presented new data regarding novel therapies. Lombard-Bohas et al. (Abstract #224) presented new data from the RADIANT-3 trial and Shen et al. (Abstract #322) looked at the use of octreotide in elderly patients with carcinoid syndrome.

Original languageEnglish (US)
Pages (from-to)152-154
Number of pages3
JournalJournal of the Pancreas
Volume14
Issue number2
StatePublished - Mar 2013

Fingerprint

Gastrointestinal Neoplasms
San Francisco
Neuroendocrine Tumors
Therapeutics
Octreotide
Carcinoid Tumor
Gastrointestinal Tract
Neoplasms
Epithelial Cells
Gastro-enteropancreatic neuroendocrine tumor
Hormones

Keywords

  • Carcinoid tumor
  • Neuroendocrine tumors
  • Octreotide
  • Therapeutics
  • TOR serine-threonine kinases

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Hepatology

Cite this

Novel agents in gastroenteropancreatic neuroendocrine tumors : Highlights from the "2013 ASCO gastrointestinal cancers symposium". San Francisco, CA, USA. january 24-26, 2013. / Stevenson, Ryan; Libutti, Steven K.; Saif, Muhammad Wasif.

In: Journal of the Pancreas, Vol. 14, No. 2, 03.2013, p. 152-154.

Research output: Contribution to journalArticle

@article{7781910809de46629229fb9d1e6d1b10,
title = "Novel agents in gastroenteropancreatic neuroendocrine tumors: Highlights from the {"}2013 ASCO gastrointestinal cancers symposium{"}. San Francisco, CA, USA. january 24-26, 2013",
abstract = "Neuroendocrine tumors (NET) are a diverse group of tumors that derive from epithelial cells with neuroendocrine differentiation. Gastroenteropancreatic neuroendocrine tumors are a subset of NET that arises in the gastrointestinal tract. Clinical symptoms and presentations vary depending on the location and hormones produced by the tumor. Treatment of advanced and metastatic gastroenteropancreatic NETs has traditionally been difficult with few systemic treatment options. In 2011, two new targeted therapies, everolimus and sunitinib were approved for treatment of pancreatic NET leading to increased interest in novel agents active in gastroenteropancreatic NETs. At the 2013 ASCO Gastrointestinal Cancers Symposium two abstracts presented new data regarding novel therapies. Lombard-Bohas et al. (Abstract #224) presented new data from the RADIANT-3 trial and Shen et al. (Abstract #322) looked at the use of octreotide in elderly patients with carcinoid syndrome.",
keywords = "Carcinoid tumor, Neuroendocrine tumors, Octreotide, Therapeutics, TOR serine-threonine kinases",
author = "Ryan Stevenson and Libutti, {Steven K.} and Saif, {Muhammad Wasif}",
year = "2013",
month = "3",
language = "English (US)",
volume = "14",
pages = "152--154",
journal = "Journal of the Pancreas",
issn = "1590-8577",
publisher = "E.S. Burioni Ricerche Bibliografiche",
number = "2",

}

TY - JOUR

T1 - Novel agents in gastroenteropancreatic neuroendocrine tumors

T2 - Highlights from the "2013 ASCO gastrointestinal cancers symposium". San Francisco, CA, USA. january 24-26, 2013

AU - Stevenson, Ryan

AU - Libutti, Steven K.

AU - Saif, Muhammad Wasif

PY - 2013/3

Y1 - 2013/3

N2 - Neuroendocrine tumors (NET) are a diverse group of tumors that derive from epithelial cells with neuroendocrine differentiation. Gastroenteropancreatic neuroendocrine tumors are a subset of NET that arises in the gastrointestinal tract. Clinical symptoms and presentations vary depending on the location and hormones produced by the tumor. Treatment of advanced and metastatic gastroenteropancreatic NETs has traditionally been difficult with few systemic treatment options. In 2011, two new targeted therapies, everolimus and sunitinib were approved for treatment of pancreatic NET leading to increased interest in novel agents active in gastroenteropancreatic NETs. At the 2013 ASCO Gastrointestinal Cancers Symposium two abstracts presented new data regarding novel therapies. Lombard-Bohas et al. (Abstract #224) presented new data from the RADIANT-3 trial and Shen et al. (Abstract #322) looked at the use of octreotide in elderly patients with carcinoid syndrome.

AB - Neuroendocrine tumors (NET) are a diverse group of tumors that derive from epithelial cells with neuroendocrine differentiation. Gastroenteropancreatic neuroendocrine tumors are a subset of NET that arises in the gastrointestinal tract. Clinical symptoms and presentations vary depending on the location and hormones produced by the tumor. Treatment of advanced and metastatic gastroenteropancreatic NETs has traditionally been difficult with few systemic treatment options. In 2011, two new targeted therapies, everolimus and sunitinib were approved for treatment of pancreatic NET leading to increased interest in novel agents active in gastroenteropancreatic NETs. At the 2013 ASCO Gastrointestinal Cancers Symposium two abstracts presented new data regarding novel therapies. Lombard-Bohas et al. (Abstract #224) presented new data from the RADIANT-3 trial and Shen et al. (Abstract #322) looked at the use of octreotide in elderly patients with carcinoid syndrome.

KW - Carcinoid tumor

KW - Neuroendocrine tumors

KW - Octreotide

KW - Therapeutics

KW - TOR serine-threonine kinases

UR - http://www.scopus.com/inward/record.url?scp=84875033486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875033486&partnerID=8YFLogxK

M3 - Article

C2 - 23474560

AN - SCOPUS:84875033486

VL - 14

SP - 152

EP - 154

JO - Journal of the Pancreas

JF - Journal of the Pancreas

SN - 1590-8577

IS - 2

ER -